Orexo AB Reports Q2 2025 Financial Results

Orexo AB ( (ORXOF) ) has released its Q2 earnings. Here is a breakdown of the information Orexo AB presented to its investors.

Orexo AB is a commercial-stage pharmaceutical company specializing in developing drugs using advanced drug delivery technologies, with a focus on addressing opioid dependence in the US market. In its Q2 2025 earnings report, Orexo highlighted a decline in total net revenues to SEK 118.2 million, impacted by currency fluctuations and a non-recurring rebate payment. The company’s EBITDA was negative at SEK -10.1 million, with net earnings also in the red at SEK -39.8 million. Despite these challenges, Orexo’s US Commercial segment maintained stable revenues, and the company reported progress in its development pipeline, particularly with its AmorphOX® technology and products like OX640 for anaphylaxis treatment. Orexo’s management remains optimistic about achieving a positive EBITDA for the full year 2025, emphasizing the strategic importance of its AmorphOX platform and ongoing R&D projects. The company is focused on leveraging partnerships to expand its presence in the pharmaceutical market, with a particular interest in larger molecules and vaccine development.